Literature DB >> 29256049

A Pilot Study of the Normative Range of Overnight Urinary Free Cortisol Corrected for Creatinine in Children.

Ole D Wolthers1, Sabine Mersmann2, Sanjeeva Dissanayake3.   

Abstract

BACKGROUND: For more than a decade, urinary free cortisol corrected for creatinine (OUFCC) has been used to assess the systemic bioactivity of inhaled corticosteroids in children with asthma. Paediatric normative ranges, however, have not been established. The aim of the present study was to define a preliminary range for OUFCC in Tanner stage 1 children.
METHODS: A post hoc analysis was performed of 26 Tanner stage one children (aged 5-11 years) with mild asthma only requiring prn (pro re nata) treatment with short-acting β2-agonists, who participated in a 3-way cross-over knemometry study. The study comprised a run-in, two washout periods and three treatment periods (2 weeks each). Urine was collected at the end of each period. A normative range was derived using the 95% prediction interval for the geometric mean OUFCC, calculated from run-in and washout periods.
RESULTS: Twenty-six children contributed 41 OUFCC values. The geometric mean OUFCC was 9.0 nmol/mmol (95% PI: 3.6, 22.7 nmol/mmol).
CONCLUSIONS: The OUFCC preliminary normative range was 3.6 to 22.7 nmol/mmol in Tanner stage one children. A larger study in healthy children is warranted to confirm these findings and to assess potential differences in OUFCC across developmental stages and age groups, and by gender and race. EUDRACT NUMBER: 2013-004719-32, CLINICALTRIALS. GOV IDENTIFIER: NCT02063139.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29256049     DOI: 10.1007/s40261-017-0609-x

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  35 in total

1.  Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler.

Authors:  O J Dempsey; A M Wilson; W J Coutie; B J Lipworth
Journal:  Chest       Date:  1999-10       Impact factor: 9.410

2.  Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers.

Authors:  Arun Nair; Lorna McKinlay; Peter Williamson; Philip Short; Patricia Burns; Brian J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  2011-01-15       Impact factor: 2.953

3.  Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics.

Authors:  A M Wilson; L C McFarlane; B J Lipworth
Journal:  Am J Respir Crit Care Med       Date:  1997-10       Impact factor: 21.405

4.  Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity.

Authors:  A M Wilson; L C McFarlane; B J Lipworth
Journal:  J Allergy Clin Immunol       Date:  1998-04       Impact factor: 10.793

5.  Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.

Authors:  D J Clark; A Grove; R I Cargill; B J Lipworth
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

6.  Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.

Authors:  S J Fowler; L C Orr; A M Wilson; E J Sims; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

7.  Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers.

Authors:  A M Wilson; L C McFarlane; B J Lipworth
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

8.  Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens.

Authors:  H D McIntyre; C A Mitchell; S D Bowler; J G Armstrong; J A Wooler; D M Cowley
Journal:  Thorax       Date:  1995-12       Impact factor: 9.139

9.  A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination.

Authors:  Arun Nair; Karine Clearie; Daniel Menzies; Karen Meldrum; Lesley McFarlane; Brian J Lipworth
Journal:  Pulm Pharmacol Ther       Date:  2009-08       Impact factor: 3.410

10.  Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.

Authors:  Tom C Fardon; Daniel K C Lee; Kay Haggart; Lesley C McFarlane; Brian J Lipworth
Journal:  Am J Respir Crit Care Med       Date:  2004-06-07       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.